KMTS on Nasdaq
KESTRA MEDICAL TECHNOLOGIES, LTD.
Surgical and medical instruments and apparatus company in Bermuda. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with NeuroPace Inc, Pulmonx Corp or Beta Bionics, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2026
51.4%Gross margin2
-141.6%Operating margin2
-138.4%Net margin2
59.0%Revenue growth, 20262
-50.7%Return on equity2
0.16×Debt to equity2
-$116.6MFree cash flow2
Where the money goes
Where each dollar of revenue went, fiscal 2026
- Cost of revenue20¢$46.3M
- Research and development8¢$19.5M
- Selling, general and admin71¢$164.1M
- Income tax0¢$294.0K
Out of $95.1M in revenue.2 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-04-30 | 2025-04-30 |
|---|---|---|
| Revenue | $95.1M | $59.8M |
| Cost of revenue | $46.3M | $35.6M |
| Gross profit | $48.9M | $24.2M |
| Research and development | $19.5M | $15.7M |
| Selling, general and administrative | $164.1M | $114.9M |
| Total operating expenses | $183.6M | $130.6M |
| Loss from operations | -$134.7M | -$106.4M |
| Interest expense | $7.5M | $7.7M |
| Interest income | -$8.4M | -$3.2M |
| Other expense (income) | -$2.6M | $2.8M |
| Net loss before provision for income taxes | -$131.3M | -$113.7M |
| Provision for income taxes | $294.0K | $135.0K |
| Less: Undeclared preferred stock dividends | $12.3M | |
| Net loss attributable to common shareholders, basic | -$131.6M | -$126.1M |
| Net loss attributable to common shareholders, diluted | -$131.6M | -$126.1M |
| Net loss per share attributable to common shareholders, basic | -$2.43 | -$5.13 |
| Net loss per share attributable to common shareholders, diluted | -$2.43 | -$5.13 |
| Weighted average shares of common share outstanding, basic | 54.2M shares | 24.6M shares |
| Weighted average shares of common share outstanding, diluted | 54.2M shares | 24.6M shares |
| Net loss | -$131.6M | -$113.8M |
| Unrealized loss on marketable securities | -$218.0K | |
| Comprehensive loss | -$131.8M | -$113.8M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.2
| Period ending | 2026-04-30 | 2025-12-31 | 2025-04-30 | 2024-04-30 |
|---|---|---|---|---|
| Cash and cash equivalents | $99.7M | $237.6M | ||
| Short-term investments | $96.7M | |||
| Accounts receivable, net | $14.5M | $8.1M | ||
| Disposable medical equipment supplies | $6.7M | $6.6M | ||
| Prepaid expenses and other current assets | $4.7M | $3.1M | ||
| Total current assets | $222.4M | $255.3M | ||
| Long-term investments | $65.8M | |||
| Right-of-use assets | $3.4M | $1.6M | $2.1M | |
| Deposits | $1.8M | $2.0M | ||
| Restricted cash | $334.0K | $334.0K | ||
| Property and equipment, net | $59.1M | $34.8M | ||
| Other long-term assets | $5.8M | $1.2M | ||
| Total assets | $358.5M | $295.7M | ||
| Accounts payable | $27.3M | $24.0M | ||
| Accrued liabilities | $23.0M | $13.8M | ||
| Operating lease liabilities, current portion | $31.0K | $187.0K | ||
| Total current liabilities | $50.4M | $38.0M | ||
| Operating lease liabilities, net of current portion | $4.1M | $3.0M | ||
| Warrant liabilities | $1.4M | $8.1M | ||
| Other long-term liabilities | $306.0K | $140.0K | ||
| Long-term debt, net | $42.6M | $41.1M | ||
| Total liabilities | $98.8M | $90.3M | ||
| Common Shares, $1.00 par value; 100,000,000 shares authorized as of April 30, 2026 and April 30, 2025; 58,383,924 issued and outstanding as of April 30, 2026 and 51,348,656 shares issued and outstanding as of April 30, 2025 | $58.4M | $51.3M | ||
| Additional paid-in capital | $853.4M | $674.3M | ||
| Accumulated other comprehensive loss | -$218.0K | |||
| Accumulated deficit | -$651.9M | -$520.2M | ||
| Total shareholders' equity | $259.7M | $205.4M | -$209.4M | |
| Total liabilities and shareholders' equity | $358.5M | $295.7M | ||
| Common stock, par value | $1.00 | $1.00 | ||
| Common stock, shares authorized | 100.0M shares | 100.0M shares | ||
| Common stock, shares issued | 58.4M shares | 51.3M shares | ||
| Common stock, shares outstanding | 58.4M shares | 51.3M shares |
| Period ending | 2026-04-30 | 2025-12-31 | 2025-04-30 | 2024-04-30 |
|---|---|---|---|---|
| Cash and cash equivalents | $99.7M | $237.6M | ||
| Short-term investments | $96.7M | |||
| Accounts receivable, net | $14.5M | $8.1M | ||
| Disposable medical equipment supplies | $6.7M | $6.6M | ||
| Prepaid expenses and other current assets | $4.7M | $3.1M | ||
| Total current assets | $222.4M | $255.3M | ||
| Long-term investments | $65.8M | |||
| Right-of-use assets | $3.4M | $1.6M | $2.1M | |
| Deposits | $1.8M | $2.0M | ||
| Restricted cash | $334.0K | $334.0K | ||
| Property and equipment, net | $59.1M | $34.8M | ||
| Other long-term assets | $5.8M | $1.2M | ||
| Total assets | $358.5M | $295.7M | ||
| Accounts payable | $27.3M | $24.0M | ||
| Accrued liabilities | $23.0M | $13.8M | ||
| Operating lease liabilities, current portion | $31.0K | $187.0K | ||
| Total current liabilities | $50.4M | $38.0M | ||
| Operating lease liabilities, net of current portion | $4.1M | $3.0M | ||
| Warrant liabilities | $1.4M | $8.1M | ||
| Other long-term liabilities | $306.0K | $140.0K | ||
| Long-term debt, net | $42.6M | $41.1M | ||
| Total liabilities | $98.8M | $90.3M | ||
| Common Shares, $1.00 par value; 100,000,000 shares authorized as of April 30, 2026 and April 30, 2025; 58,383,924 issued and outstanding as of April 30, 2026 and 51,348,656 shares issued and outstanding as of April 30, 2025 | $58.4M | $51.3M | ||
| Additional paid-in capital | $853.4M | $674.3M | ||
| Accumulated other comprehensive loss | -$218.0K | |||
| Accumulated deficit | -$651.9M | -$520.2M | ||
| Total shareholders' equity | $259.7M | $205.4M | -$209.4M | |
| Total liabilities and shareholders' equity | $358.5M | $295.7M | ||
| Common stock, par value | $1.00 | $1.00 | ||
| Common stock, shares authorized | 100.0M shares | 100.0M shares | ||
| Common stock, shares issued | 58.4M shares | 51.3M shares | ||
| Common stock, shares outstanding | 58.4M shares | 51.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-04-30 | 2025-04-30 |
|---|---|---|
| Net loss | -$131.6M | -$113.8M |
| Depreciation and amortization | $8.7M | $8.0M |
| Loss on disposal of property and equipment | $1.2M | $1.3M |
| Reserve for equipment and supplies | $2.4M | $754.0K |
| Provision for uncollectible accounts receivable | $2.6M | $2.7M |
| Amortization (accretion) of premiums (discounts) on securities, net | -$106.0K | |
| Interest paid-in-kind | $855.0K | |
| Amortization of debt discounts and issuance costs | $1.9M | $1.4M |
| Share-based compensation expense | $33.6M | $24.3M |
| Non-cash lease expense | $326.0K | $416.0K |
| Deferred income tax expense | $166.0K | $64.0K |
| Change in fair value of warrant liabilities | -$2.7M | $2.6M |
| Disposable medical equipment supplies | -$458.0K | -$3.4M |
| Prepaid expenses and other current assets | -$563.0K | -$1.9M |
| Accounts receivable | -$9.1M | -$8.8M |
| Accounts payable | $4.3M | $2.8M |
| Accrued liabilities | $8.2M | $4.6M |
| Operating lease liabilities | -$685.0K | $370.0K |
| Other long-term assets | $40.0K | $40.0K |
| Net cash used in operating activities | -$81.7M | -$77.6M |
| Purchases of property and equipment | -$34.9M | -$22.9M |
| Deposits for medical rental equipment | -$528.0K | -$655.0K |
| Refund of deposits for medical rental equipment | $184.0K | $283.0K |
| Investment in equity security | -$5.0M | |
| Purchase of marketable securities | -$163.0M | |
| Net cash used in investing activities | -$203.3M | -$23.3M |
| Proceeds from issuance of redeemable preferred stock | $103.4M | |
| Proceeds from issuance of common stock | $149.3M | $215.8M |
| Proceeds from issuance of stock to non-controlling interest | $17.1M | |
| Proceeds from capital contributions | $2.4M | |
| Payments of IPO offering costs | -$3.5M | |
| Payment of equity issuance costs | -$2.5M | -$3.2M |
| Deemed dividend for payments to third party on behalf of shareholder | -$323.0K | -$1.7M |
| Proceeds from stock option exercises | $593.0K | |
| Net cash provided by financing activities | $147.1M | $330.3M |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -$137.9M | $229.3M |
| Purchases of property and equipment in accrued liabilities and accounts payable | $8.3M | $7.0M |
| Exercise of liability classified warrant | $4.1M | |
| Remeasurement of lease liability | $1.6M | |
| Equity offering costs incurred but not yet paid | $415.0K | $1.9M |
| Deemed dividend for payments to third party on behalf of shareholder included in accrued liabilities and accounts payable | $172.0K | |
| Issuance of warrants related to long term debt | $5.4M | |
| Conversion of redeemable preferred stock into Common Shares on completion of IPO | $280.5M | |
| Income taxes paid | $13.0K | $83.0K |
| Interest paid | $5.6M | $4.9M |
No quarter-by-quarter statement was filed.
Compare KESTRA MEDICAL TECHNOLOGIES, LTD. with another company
Leadership
Who has led KESTRA MEDICAL TECHNOLOGIES, LTD., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
- Chief financial officerVaseem Mahboob Mar 6, 2025 to now8
Board members and other officers (14)
- Chief Commercial OfficerAlfred J. Ford Jr. Mar 6, 2025 to now9
- OfficerBrian Daniel Webster Mar 6, 2025 to now10
- OfficerTraci S. Umberger Mar 6, 2025 to now11
- Chief Business OfficerTimothy P. Moran Nov 10, 2025 to now12
- Board memberBrian Daniel Webster Mar 6, 2025 to now10
- Board memberChristopher R. Gordon Mar 6, 2025 to Mar 6, 202513
- Board memberKevin C. Reilly Mar 6, 2025 to now14
- Board memberMary Kay Ladone Mar 6, 2025 to now15
- Board memberMaxwell Bikoff Mar 6, 2025 to Mar 6, 202516
- Board memberRaymond W. Cohen Mar 6, 2025 to now17
- Board memberToby Auwerter Mar 6, 2025 to Mar 6, 202518
- Board memberTraci S. Umberger Mar 6, 2025 to now11
- Board memberConor Hanley Jun 12, 2025 to now19
- Board memberElizabeth Kwo Sep 8, 2025 to now20
Filings
173 filings to the SEC since October 2021: 2 annual reports, 5 quarterly reports, 14 major events, 69 insider forms, 9 large holders, 74 other. The latest 20:
- Oct 1, 20264 EDGAR
- Sep 30, 2026144 EDGAR
- Sep 23, 20264 EDGAR
- Sep 21, 2026144 EDGAR
- Sep 14, 202610-Q EDGAR
- Sep 14, 20268-K EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20264 EDGAR
- Sep 10, 20268-K EDGAR
- Sep 10, 20264 EDGAR
- Sep 8, 2026144 EDGAR
- Sep 8, 2026144 EDGAR
- Sep 8, 2026144 EDGAR
- Sep 8, 2026144 EDGAR
- Aug 18, 20264 EDGAR
- Aug 17, 2026144 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
The 173 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
39 open-market trades by officers, directors and large owners since October 2021: 4 buys and 35 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 21, 2026 | Kwo ElizabethDirector | Sale | 4,010 | $24.26 | $97.3K | Form 4 |
| Sep 8, 2026 | Hanley ConorDirector | Sale | 5,694 | $25.25 | $143.8K | Form 4 |
| Sep 8, 2026 | Reilly Kevin CDirector | Sale | 2,932 | $25.13 | $73.7K | Form 4 |
| Sep 8, 2026 | Ladone Mary KayDirector | Sale | 3,908 | $25.20 | $98.5K | Form 4 |
| Sep 8, 2026 | Schwartz Jeffrey LawrenceDirector | Sale | 3,890 | $25.18 | $98.0K | Form 4 |
| Aug 17, 2026 | Webster Brian DanielSee Remarks | Sale | 15,000 | $27.48 | $412.2K | Form 4 |
| Aug 7, 2026 | Mahboob VaseemChief Financial Officer | Sale | 26,287 | $25.88 | $680.3K | Form 4 |
| Aug 4, 2026 | Ford Alfred J JrChief Commercial Officer | Sale | 6,275 | $24.09 | $151.2K | Form 4 |
| Aug 4, 2026 | Mahboob VaseemChief Financial Officer | Sale | 6,995 | $24.68 | $172.6K | Form 4 |
| Aug 4, 2026 | Umberger Traci SSee Remarks | Sale | 3,580 | $24.04 | $86.1K | Form 4 |
| Aug 4, 2026 | Webster Brian DanielSee Remarks | Sale | 51,900 | $24.52 | $1.3M | Form 4 |
| Aug 3, 2026 | Moran Timothy P.Chief Business Officer | Sale | 2,380 | $23.76 | $56.5K | Form 4 |
| Aug 3, 2026 | Ford Alfred J JrChief Commercial Officer | Sale | 13,015 | $23.90 | $311.1K | Form 4 |
| Aug 3, 2026 | Mahboob VaseemChief Financial Officer | Sale | 5,391 | $23.80 | $128.3K | Form 4 |
| Aug 3, 2026 | Umberger Traci SSee Remarks | Sale | 7,590 | $23.86 | $181.1K | Form 4 |
| Aug 3, 2026 | Webster Brian DanielSee Remarks | Sale | 13,017 | $23.92 | $311.4K | Form 4 |
| Jul 31, 2026 | Moran Timothy P.Chief Business Officer | Sale | 8,759 | $22.61 | $198.0K | Form 4 |
| Jul 31, 2026 | Ford Alfred J JrChief Commercial Officer | Sale | 8,681 | $22.61 | $196.3K | Form 4 |
| Jul 31, 2026 | Mahboob VaseemChief Financial Officer | Sale | 8,817 | $22.61 | $199.4K | Form 4 |
| Jul 31, 2026 | Umberger Traci SSee Remarks | Sale | 8,752 | $22.60 | $197.8K | Form 4 |
All 39 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- PRICE T ROWE ASSOCIATES INC /MD/SCHEDULE 13G/A, 3 filings Feb 17, 2026 to Aug 14, 202621
- Bain Charger Holdings, L.P.SCHEDULE 13G/A, 2 filings May 15, 2025 to Feb 17, 202622
- Endeavour Medtech Growth II LPSCHEDULE 13G/A, 2 filings May 15, 2025 to Feb 17, 202623
- FMR LLCSCHEDULE 13G/A, 2 filings May 12, 2025 to Oct 7, 202524
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10SEC EDGARBrian Daniel Webster, Officer
- 11SEC EDGARTraci S. Umberger, Officer
- 12
- 13SEC EDGARChristopher R. Gordon, Board member
- 14SEC EDGARKevin C. Reilly, Board member
- 15SEC EDGARMary Kay Ladone, Board member
- 16SEC EDGARMaxwell Bikoff, Board member
- 17SEC EDGARRaymond W. Cohen, Board member
- 18SEC EDGARToby Auwerter, Board member
- 19SEC EDGARConor Hanley, Board member
- 20SEC EDGARElizabeth Kwo, Board member
- 21
- 22
- 23
- 24